drugset / Trial / NCT03067376

A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body

NCT03067376

Phase 1 Completed 9 enrolled Corcept Therapeutics
NaSingle-groupOpen-labelBasic science

Summary

The study was designed to evaluate how CORT125134 is taken up, broken down and removed from the body when given as an oral capsule to healthy subjects.

Timeline

Start
2016-08
Primary completion
2016-09
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Relacorilant Small molecule 125 mg Oral

Indications

No indication recorded.